biostudies-literatureUnknown11(1)Leuchter MK<h4>Introduction</h4>Brain network dysfunction, particularly within the default mode network (DMN), is an increasingly apparent contributor to the clinical progression of Alzheimer's disease (AD). Repetitive transcranial magnetic stimulation (rTMS) can target key DMN hubs, maintain signaling function, and delay or improve clinical outcomes in AD. Here, we present the rationale and design of a study using off-the-shelf equipment and the latest clinical evidence to expand on prior rTMS work and reduce participant burden in the process.<h4>Methods</h4>We will conduct a two-stage trial of large-coil rTMS targeting the precuneus (a key hub in the DMN affected by AD) in 54 participants with mild to moderate Alzheimer's Clinical Syndrome focused primarily on determining tolerability and feasibiliAlzheimer's & dementia (New York, N. Y.)e70043https://www.ebi.ac.uk/biostudies/studies/S-EPMC11891574biostudies-literatureBroad repetitive transcranial magnetic stimulation (rTMS) of the precuneus in Alzheimer's disease: A rationale and study design.PMC11891574Ngo DDurbin KASuthana NLeuchter MKElashoff DJackson NJFogel BLCorlier JMatthews CChang TSWong DVossel KLeuchter AFOughli HABitan GfalseBroad repetitive transcranial magnetic stimulation (rTMS) of the precuneus in Alzheimer's disease: A rationale and study design.<h4>Introduction</h4>Brain network dysfunction, particularly within the default mode network (DMN), is an increasingly apparent contributor to the clinical progression of Alzheimer's disease (AD). Repetitive transcranial magnetic stimulation (rTMS) can target key DMN hubs, maintain signaling function, and delay or improve clinical outcomes in AD. Here, we present the rationale and design of a study using off-the-shelf equipment and the latest clinical evidence to expand on prior rTMS work and reduce participant burden in the process.<h4>Methods</h4>We will conduct a two-stage trial of large-coil rTMS targeting the precuneus (a key hub in the DMN affected by AD) in 54 participants with mild to moderate Alzheimer's Clinical Syndrome focused primarily on determining tolerability and feasibili2025-01-01T00:00:00Z2025 Jan-Mar2026-06-01T20:12:18.849Z2025-04-07T07:49:03.857ZS-EPMC118915744006591710.1002/trc2.70043